Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Ia A Sigidin"'
Autor:
E L Nasonov, G V Lukina, Ia A Sigidin, L A Bazevich, T I Zlobina, R G Kamalova, L A Kniazeva, V I Mazurov, L V Men'shikova, A É Sizikov, E A Smirnova, N A Fofonova, T V Shabalina, L M Shkil', N V Iudina, S S Iakushin
Publikováno v:
Терапевтический архив, Vol 80, Iss 8, Pp 57-62 (2008)
Aim. To assess efficacy and tolerance to anti-B-cell drug rituximab in therapy of rheumatoid arthritis (RA) by the data of RF register of this drug. Material and methods. Rituximab was studied in 42 patients with high RA activity. 37 patients receive
Externí odkaz:
https://doaj.org/article/1b6248ea4ea043a78744b0e22705a154
Publikováno v:
Терапевтический архив, Vol 80, Iss 5, Pp 30-37 (2008)
Aim. To evaluate objectively therapeutic potentialities of a novel method of biological therapy - blocking interferon gamma (IF-γ) - by means of a comparative analysis of using antibodies to IF-g (anti-IF-γ) and tumor necrosis factor alpha (anti-TN
Externí odkaz:
https://doaj.org/article/679671c1494341b7bec84ad9c6b2373f
Publikováno v:
Terapevticheskii arkhiv. 81(8)
To analyse the data on infliximab administration (efficacy, tolerance, toxicity) in patients with rheumatoid arthritis (RA) in Russia by clinical evidence provided by the multicenter observation trial.The register included 297 patients with a documen
Autor:
Ia A, Sigidin, G V, Lukina
Publikováno v:
Vestnik Rossiiskoi akademii meditsinskikh nauk. (6)
State-of-the-art state of biological therapy of rheumatoid arthritis is analyzed. Its pathogenetic reasons are represented. Main direction of this therapy, such as blocking of tumor necrosis factor alpha and interleukin-1, inhibition of interaction b
Publikováno v:
Terapevticheskii arkhiv. 75(5)
Autor:
G V, Lukina, Ia A, Sigidin, N V, Chichasova, R M, Balabanova, A G, Belenkiĭ, G R, Imametdinova, V G, Barskova, A G, Bochkova, D A, Gukasian, O N, Egorova, D E, Karateev, I R, Kolosova, E Iu, Loginova, E Iu, Pudovkina, M L, Stanislav, L A, Taukumova, T P, Fedina, E L, Nasonov
Publikováno v:
Terapevticheskii arkhiv. 75(5)
To study effectiveness and tolerance of monoclonal antibodies to tumor necrosis factor (the drug remicade) in patients with rheumatoid arthritis (RA).Remicade treatment results are considered for 25 RA patients receiving methotrexate the activity of
Publikováno v:
Terapevticheskii arkhiv. 73(5)
Objective evaluation of the effectiveness and tolerance of antibodies to interferon-gamma (TNF-gamma) vs those to tumor necrosis factor-alpha (TNF-a) and placebo in patients with rheumatoid arthritis (RA).A double blind randomised controlled trial of
Autor:
Ia A, Sigidin
Publikováno v:
Vestnik Rossiiskoi akademii meditsinskikh nauk. (12)
The paper deals with the achievements of the Institute of Rheumatology in antirheumatic therapy, among them there are methods of objective assessment of antirheumatic drugs, the first use of antimalarials in the treatment of chronic rheumatic fever,
Publikováno v:
Terapevticheskii arkhiv. 70(5)
Investigation of efficacy of antibodies ot interferons in rheumatoid arthritis (RA) versus relevant efficacy of the tumor necrosis factor (TNF), comparison of the above cytokines in monotherapy and combined treatment.An open controlled randomized tri
Autor:
V A, Nasonova, Ia A, Sigidin, Iu V, Murav'ev, O I, Lebedeva, V I, Burtsev, Z P, Rashchupkina, V P, Krikunov, A V, Kuzin, E L, Nasonov, N V, Chichasova
Publikováno v:
Terapevticheskii arkhiv. 67(1)
A clinical trial of arthrotek (Searle) in 60 RA patients aged 16-77 years demonstrated its high anti-inflammatory activity in 47 of them. These patients have received a complete treatment course, 10 patients were not included in the overall estimatio